{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'The Full Analysis Set (FAS) will be used for the efficacy analysis on os and PFS1. All subjects', 'who are randomized will be included in the FAS. For time to event endpoints including OS and', 'PFS1 log-rank test stratified by randomization stratification factors including liver metastasis,', 'baseline ECOG PS and regions of the world at baseline will be used to compare the 2 treatment', 'arms. The hazard ratio and corresponding 95% confidence interval from the stratified Cox', 'proportional hazards regression model will also be presented. The median OS, PFS1 and DOR will', 'be estimated using the Kaplan-Meier method and will be reported along with the corresponding', '95% confidence interval by treatment arm.', 'ORR and DCR will be compared between treatment arms using Cochran-Mantel-Haenszel test,', 'stratified by the same stratification factors used in time to event analyses. The difference in', 'response rates between the treatment arms will be estimated along with the corresponding 95%', 'confidence interval.', 'Safety:', 'The Safety Analysis Set (SAF) will be used for the safety analysis. All subjects who are', 'randomized and received study drug will be included in the SAF. The frequency of AEs and the', 'serious AEs will be summarized by MedDRA system organ class and preferred term. In addition,', 'summary statistics will be provided for the following safety parameters:', 'Laboratory values', 'Vital sign measurements', 'ECOG PS', 'Pharmacokinetics:', 'Descriptive statistics (e.g., number, mean, standard deviation, minimum, median, maximum,', 'coefficient of variation and geometric mean) will be provided for plasma or serum concentrations', 'of TAb, ADC and MMAE. The incidence of ATA to EV will be summarized by cycle and overall,', 'and possible relationship to pharmacokinetics explored. Additional model-based analyses and', 'exposure response may be performed and reported separately.', '14 Sep 2020', 'Astellas', 'Page 30 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'V.', 'FLOW CHART AND SCHEDULE OF ASSESSMENTS', 'Figure 1', 'Study Schema', '1:1 Randomization/', 'Stratification', 'Treatment: Days 1, 8 &', 'ARM A: Enfortumab', '15 of each 28-day cycle', 'Follow-up for PFS1 &', 'Vedotin', 'until PD or', 'PFS2/OS', 'Screening', 'N=300', 'discontinuation', 'Enrollment', 'Day -28 to Day 1', 'ARM B: Docetaxel,', 'Paclitaxel or Vinflunine', 'Treatment: Day 1 of', 'Follow-up for PFS1 &', 'N=300', 'each 21-day cycle until', 'PFS2/OS', 'PD or discontinuation', 'OS: overall survival; PD: progressive disease; PFS: progression free survival; PFS1 progression free survival on study therapy; PFS2: progression free survival on subsequent therapy', '*Imaging for both Arms will be performed at baseline and every 56 days ( 7 days) from the first dose of study treatment throughout the study until radiological', 'disease progression, lost to follow-up, withdrawal of study consent, or start of a subsequent anti-cancer therapy. If a subject discontinues study drug prior to', 'radiographic disease progression (i.e., PFS1), the subject should continue to undergo imaging assessment (including brain/bone imaging', 'when', 'indicated', 'and', 'collection of tumor measurements) every 56 days ( 7 days) in the post treatment follow-up period until PFS1 is documented per the investigator or the subject starts', 'another cancer treatment, whichever occurs earlier. After PFS1, subjects will be followed in the long-term follow-up period per institutional guidelines, but not less', 'frequently than every 3 months to confirm survival status and collect subsequent anticancer treatment details and progression status until PFS2 is documented or the', 'subject starts another cancer treatment, whichever occurs earlier. Phone contact with subject is sufficient for follow-up. Additional follow-up contacts may be', 'required per sponsor request for analysis purposes.', '14 Sep 2020', 'Astellas', 'Page 31 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}